Review
Oncology
Carmen Criscitiello, Chiara Corti, Gabriella Pravettoni, Giuseppe Curigliano
Summary: ICIs have become a significant development in cancer therapy, with recent trials in breast cancer showing promising results. However, the safety of ICIs is affected by irAEs, requiring a focus on managing these adverse events.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Mungyo Jung, Mikyung Kang, Byung-Seok Kim, Jihye Hong, Cheesue Kim, Choong-Hyun Koh, Garam Choi, Yeonseok Chung, Byung-Soo Kim
Summary: This study demonstrates the selective activation of tumor-specific T cells and enhanced antitumor efficacy of alpha CTLA-4 therapy by delivering the antibody through dendritic cell-derived nanovesicles, which reduces adverse reactions.
ADVANCED MATERIALS
(2022)
Review
Oncology
Kathryn DeCarli, Jonathan Strosberg, Khaldoun Almhanna
Summary: Immune checkpoint inhibitors have revolutionized cancer treatment, but their effectiveness in gastrointestinal cancers is still being explored. This article provides an overview of their use in treating different types of gastrointestinal cancers.
Review
Gastroenterology & Hepatology
Rocio Sedano, Daniel Cabrera, Andrea Jimenez, Christopher Ma, Vipul Jairath, Marco Arrese, Juan Pablo Arab
Summary: This article reviews the role of immune checkpoint inhibitors (ICI) in cancer treatment, which have shown clinical efficacy in cancer types that do not respond well to conventional chemotherapy. However, these treatments can lead to immune-related adverse events, particularly affecting the digestive system.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)
Review
Biochemistry & Molecular Biology
Evangelos Koustas, Eleni-Myrto Trifylli, Panagiotis Sarantis, Nikolaos Papadopoulos, Eleni Karapedi, Georgios Aloizos, Christos Damaskos, Nikolaos Garmpis, Anna Garmpi, Kostas A. Papavassiliou, Michalis V. Karamouzis, Athanasios G. Papavassiliou
Summary: Gastrointestinal cancer is a highly lethal malignancy and remains a major challenge for cancer treatment options. Despite current treatment strategies, the survival rates for patients with advanced disease are still low. Understanding the molecular mechanisms that influence tumor progression and developing optimal therapeutic strategies are urgently needed. Immunotherapeutic agents are currently being developed and assessed through clinical trials, offering new modalities and combination treatments.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, General & Internal
Preethika Mahalingam, Thomas Newsom-Davis
Summary: The use of immune checkpoint inhibitors has revolutionized cancer treatment by harnessing the immune system against cancer cells. However, these therapies can cause severe toxicity related to increased immune activity. Therefore, early detection and management of toxicities are crucial. This article focuses on diagnosing and treating common toxicities associated with immune checkpoint inhibitors.
Article
Immunology
Yaping Chen, Hao Huang, Yuan Li, Wenlu Xiao, Yingting Liu, Rongzhang Chen, Yulan Zhu, Xiao Zheng, Changping Wu, Lujun Chen
Summary: Combination immunotherapy based on immune checkpoint inhibitors (ICIs) has shown great success in cancer treatment, and the combination of ablation and immunotherapy has potential for the treatment of liver metastasis of colorectal cancer (CRC). The expression of TIGIT was up-regulated after microwave ablation (MWA), and the combination of MWA and TIGIT blockade significantly promoted the expansion and functions of CD8(+) tumor-infiltrating lymphocytes (TILs) and reshaped myeloid cells in the tumor microenvironment (TME).
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Lei Yu, Jian Zhang, Yunfeng Li
Summary: This article reviews the positive effects of hypoxia in osteosarcoma and discusses the role of immunotherapy in the tumor microenvironment. It suggests that immunotherapy may represent an innovative approach for the treatment of osteosarcoma patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Bo Li, Hui Chen, Shaohua Yang, Feng Chen, Liangliang Xu, Yan Li, Mingzhe Li, Chengming Zhu, Fangyuan Shao, Xinhua Zhang, Chuxia Deng, Leli Zeng, Yulong He, Changhua Zhang
Summary: Mesenchymal gastrointestinal cancers, specifically gastrointestinal stromal tumors (GISTs), have global impacts on human health and economy as they occur throughout the gastrointestinal tract. Surgical resections and TKIs are the primary treatments for localized and recurrent/metastatic GISTs, respectively. Despite the benefits of TKIs, drug resistance remains a significant obstacle, leading to the exploration of immunotherapy, particularly immune checkpoint inhibitors (ICIs), as an alternative choice for GIST treatment.
Article
Oncology
Mathilde Beaufils, Vincent Amodru, Manuel Tejeda, Jean Marie Boher, Christophe Zemmour, Brice Chanez, Anne Sophie Chretien, Laurent Gorvel, Gwenaelle Gravis, Damien Bruyat, Roxane Mari, Anne Madroszyk, Thomas Cuny, Anthony Goncalves, Aaron E. Lisberg, Daniel Olive, Louis Tassy, Frederic Castinetti, Philippe Rochigneux
Summary: Data mining analysis showed that immune checkpoint inhibitor (ICI)-induced dysthyroidism (DT) was associated with improved overall survival (OS), and patients with both DT and other immune-related adverse events had even longer OS.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Junaid Arshad, Philippos A. Costa, Priscila Barreto-Coelho, Brianna Nicole Valdes, Jonathan C. Trent
Summary: Gastrointestinal stromal tumors (GIST) are the most common type of gastrointestinal sarcomas, and recent treatment advancements have significantly improved patient survival rates. However, metastatic GIST patients may require multiple lines of treatment, and the potential role of immunotherapies in enhancing current therapies needs further exploration through in-depth research.
Review
Oncology
Muhammet Ozer, Charan Thej Reddy Vegivinti, Masood Syed, Morgan E. E. Ferrell, Cyndi Gonzalez Gomez, Svea Cheng, Jennifer Holder-Murray, Tullia Bruno, Anwaar Saeed, Ibrahim Halil Sahin
Summary: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of mismatch repair-deficient (MMR-D)/microsatellite instability-high (MSI-H) gastrointestinal cancers. These cancers have a high mutation burden and generate mutation-associated neoantigens (MANAs). ICIs activate T-cell immunity against these cancers, leading to significant antitumor activity. The use of ICIs as neoadjuvant therapy shows great promise, as demonstrated by deep clinical and pathological responses in clinical trials.
Article
Immunology
Shanshan Wan, Ende Zhao, Daniel Weissinger, Benjamin A. Krantz, Gregor Werba, Daniel Freeman, Lauren G. Khanna, Despina Siolas, Paul E. Oberstein, Pratip K. Chattopadhyay, Diane M. Simeone, Theodore H. Welling
Summary: Hepato-pancreatico-biliary (HPB) malignancies have high mortality and therapeutic resistance. Immune oncology (IO) therapies have shown effectiveness in solid malignancies but not in pancreatic ductal adenocarcinoma (PDA). This study investigates T cell subsets in the tumor microenvironment of HPB patients and found varying phenotypes and checkpoint receptor expression levels. Different HPB cancers exhibit different T cell states, suggesting the need for tailored treatment approaches.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Rom Leidner, Kevin Conlon, Douglas G. Mcneel, Andrea Wang-Gillam, Sumati Gupta, Robert Wesolowski, Monica Chaudhari, Nadia Hassounah, Jong Bong Lee, Lang Ho Lee, Jessica A. O'Keeffe, Nancy Lewis, George N. Pavlakis, John A. Thompson
Summary: This study investigated the efficacy and safety of NIZ985 as monotherapy and in combination with spartalizumab in the treatment of advanced solid tumors. The results showed that NIZ985 demonstrated antitumor activity and was well tolerated in patients with advanced solid tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Pharmacology & Pharmacy
Ahmed O. Elzoghby, Cristina R. Ferrone, Soldano Ferrone, Mahmoud L. Nasr
Summary: Pancreatic cancer is a highly aggressive and resistant type of cancer. This review highlights the recent advances in engineering nanomedicines to enhance the immune response against pancreatic cancer. Nanomedicines are used to increase the immunogenicity of cancer cells, deactivate cancer-associated fibroblasts, enhance the antigen-presenting capacity of dendritic cells, reverse the immunosuppressive nature of the tumor microenvironment, and improve the infiltration of cytotoxic T lymphocytes for efficient antitumor immune responses.
DRUG DISCOVERY TODAY
(2023)
